Differences in regulation of tight junctions and cell morphology between VHL mutations from disease subtypes

被引:18
作者
Bangiyeva, Valentina [1 ]
Rosenbloom, Ava [1 ]
Alexander, Ashlynn E. [1 ]
Isanova, Bella [1 ]
Popko, Timothy [1 ]
Schoenfeld, Alan R. [1 ]
机构
[1] Adelphi Univ, Dept Biol, Garden City, NY 11530 USA
基金
美国国家卫生研究院;
关键词
LINDAU TUMOR-SUPPRESSOR; HYPOXIA-INDUCIBLE-FACTOR; PROTEIN-KINASE-C; BIOLOGICALLY-ACTIVE PRODUCT; RENAL-CARCINOMA CELLS; IN-VIVO; GERMLINE MUTATIONS; SOMATIC MUTATIONS; E-CADHERIN; FAMILIAL PHEOCHROMOCYTOMA;
D O I
10.1186/1471-2407-9-229
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In von Hippel-Lindau (VHL) disease, germline mutations in the VHL tumor suppressor gene cause clear cell renal carcinomas, hemangioblastomas, and pheochromocytomas. The VHL gene product is part of an ubiquitin E3 ligase complex and hypoxia-inducible factor alpha (HIF-alpha) is a key substrate, although additional VHL functions have been described. A genotype-phenotype relationship exists in VHL disease such that specific VHL mutations elicit certain subsets of these tumors. Here, we examine VHL genotype-phenotype correlations at the cellular level, focusing on the regulation of tight junctions and cell morphology. Methods: Wild-type and various mutant VHL proteins representing VHL disease subtypes were stably expressed in 3 VHL-negative renal carcinoma cell lines. Using these cell lines, the roles of various VHL-associated cellular functions in regulation of cell morphology were investigated. Results: As a whole, type 1 mutants varied greatly from type 2 mutants, demonstrating high levels of HIF-2 alpha, cyclin D1 and alpha 5 integrin, lower p27 levels, and a spindly, fibroblastic cellular appearance. Type 2 mutations demonstrated an epithelial morphology similar to wild-type VHL in the majority of the renal cell lines used. Knockdown of p27 in cells with wild-type VHL led to perturbations of both epithelial morphology and ZO-1 localization to tight junctions. ZO-1 localization correlated well with VHL disease subtypes, with greater mislocalization observed for genotypes associated with a higher risk of renal carcinoma. HIF-2 alpha knockdown in 786-O partially restored ZO-1 localization, but did not restore an epithelial morphology. Conclusion: VHL has both HIF-alpha dependent and HIF-alpha independent functions in regulating tight junctions and cell morphology that likely impact the clinical phenotypes seen in VHL disease.
引用
收藏
页数:18
相关论文
共 98 条
[1]  
Ausubel FM., 1994, Curr. Protoc. Mol. Biol
[2]   Software and database for the analysis of mutations in the VHL gene [J].
Béroud, C ;
Joly, D ;
Gallou, C ;
Staroz, F ;
Orfanelli, MT ;
Junien, C .
NUCLEIC ACIDS RESEARCH, 1998, 26 (01) :256-258
[3]  
Bindra RS, 2002, CANCER RES, V62, P3014
[4]   Alternate choice of initiation codon produces a biologically active product of the von Hippel Lindau gene with tumor suppressor activity [J].
Blankenship, C ;
Naglich, JG ;
Whaley, JM ;
Seizinger, B ;
Kley, N .
ONCOGENE, 1999, 18 (08) :1529-1535
[5]   Fibronectin is a hypoxia-independent target of the tumor suppressor VHL [J].
Bluyssen, HAR ;
Lolkema, MPJK ;
van Beest, M ;
Boone, M ;
Snijckers, CMJT ;
Los, M ;
Gebbink, MFBG ;
Braam, B ;
Holstege, FCP ;
Giles, RH ;
Voest, EE .
FEBS LETTERS, 2004, 556 (1-3) :137-142
[6]   The specific fates of tight junction proteins in apoptotic epithelial cells [J].
Bojarski, C ;
Weiske, J ;
Schöneberg, T ;
Schröder, W ;
Mankertz, J ;
Schulzke, JD ;
Florian, P ;
Fromm, M ;
Tauber, R ;
Huber, O .
JOURNAL OF CELL SCIENCE, 2004, 117 (10) :2097-2107
[7]  
Bradley JF, 1999, AM J MED GENET, V87, P163, DOI 10.1002/(SICI)1096-8628(19991119)87:2<163::AID-AJMG7>3.0.CO
[8]  
2-A
[9]   VON HIPPEL-LINDAU (VHL) DISEASE WITH PHEOCHROMOCYTOMA IN THE BLACK-FOREST REGION OF GERMANY - EVIDENCE FOR A FOUNDER EFFECT [J].
BRAUCH, H ;
KISHIDA, T ;
GLAVAC, D ;
CHEN, F ;
PAUSCH, F ;
HOFLER, H ;
LATIF, F ;
LERMAN, MI ;
ZBAR, B ;
NEUMANN, HPH .
HUMAN GENETICS, 1995, 95 (05) :551-556
[10]   Stable suppression of tumorigenicity by virus-mediated RNA interference [J].
Brummelkamp, TR ;
Bernards, R ;
Agami, R .
CANCER CELL, 2002, 2 (03) :243-247